|Bid||19.76 x 3200|
|Ask||30.05 x 1300|
|Day's Range||19.15 - 20.01|
|52 Week Range||16.69 - 41.57|
|Beta (3Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.85|
2018 was a difficult year for The Medicines Company (MDCO) with the stock languishing as biotech investors looked elsewhere; in our view, 2019 will be a turnaround year, making this our top speculative pick, asserts biotech specialist John McCamant, editor of The Medical Technology Stock Letter.
# Medicines Co ### NASDAQ/NGS:MDCO View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.37 billion over the last one-month into ETFs that hold MDCO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
With full commercial rights in all geographies, The Medicines Company is well placed to harness the intrinsic value of inclisiran. To date, more than 2,450 patient-years of inclisiran safety data have been accumulated in the ORION program, a seven-fold (or 2,120 patient-year) increase over the total patient exposure from the ORION Phase 1 and Phase 2 trials. At the time of IDMC review, all patients in Phase 3 trials had received three doses of inclisiran or placebo.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Chesapeake Energy Corporation (NYSE: CHK) saw Chief Executive Officer Robert Lawler, Chief Financial Officer Domenic J. Dell'Osso Jr. and two other insiders add to their stakes this past week. The new The Medicines Company (NASDAQ: MDCO) CEO, Mark Timney, and two other insiders altogether added more than 180,000 shares of this biopharmaceutical company to their stakes this past week.
This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
CEO of The Medicines Co (NASDAQ:MDCO) Mark Timney bought 26,863 shares of MDCO on 12/17/2018 at an average price of $18.6 a share.
A market correction in the fourth quarter, spurred by a number of global macroeconomic concerns and rising interest rates ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being […]
The Medicines Company (MDCO) (the “Company”) today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024. The notes will be senior unsecured obligations of the Company and will mature on January 15, 2024, unless earlier converted or repurchased in accordance with their terms. The notes will be convertible prior to October 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option.
The Medicines Company (MDCO) (the “Company”) today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors. The notes will be convertible, upon certain conditions, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and J.P. Morgan Securities LLC, the initial purchaser of the notes.
The Medicines Co. said Tuesday it has appointed Mark Timney as chief executive with immediate effect. Timney comes fo the job after stints at Merck & Co., and Purdue Pharmaceuticals, as well as Zeneca Group, ICI Pharmaceuticals and Roussel Labs. he will replace Clive Meanwell, who will serve as chief innovation officer. Shares were not yet active premarket, but have fallen 24% in 2018 through Monday's close, while the S&P 500 has fallen 1.3%.
The Medicines Company (MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company’s new Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the Board to serve as Chief Innovation Officer. Alexander Denner, Ph.D., the Chairman of the Board of Directors, stated, “We are pleased to welcome Mark Timney as our new CEO.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.